Brought it over for you. Sometimes things disappear on YMB.

New Post Public Reply Private Reply Replies (1) Message Board
Fumbler WUM #109463
806
Brought it over for you. Sometimes things disappear on YMB.

Bridge18 minutes ago
Recknor’s been saying interesting things in recent ccs. This is October 13.

20:30
CR
Sure. It’s important that we make sure that we follow these extension patients. Some of these patients are close to 7 years have been on monotherapy, which is incredible. There’s 3 trials, CD01, CD02, which was the drug resistance, and then CD03. All of these have extended and we’ve got a lot of data on patients that we’re looking at to give us clues about how leronlimab is working and how it’s beneficial.

There is a Mechanism of Action when we first started with this drug that is simply binding to CCR5 as an umbrella to prevent the virus from entering cells. But what we’ve discovered is that that binding actually is an immunomodulator. And it’s fascinating because CCR5, which is what we bind to, is the actual transmission system of our immune system.

And some peoples’ immune systems, from what we’re seeing, don’t work quite right. I think as a physician clinically treating patients, I wasn’t aware of some of these problems that patients were having may actually be due to abnormal immunomodulation, and that’s [inaudible]

Leronlimab binding to this, we’re able to see that in some patients that have the transmission stuck in first or second gear, and move to fifth or sixth gear, that totally changes what the immune system is able to do. And we see really a lot of that has to do with leakiness of vessels. I won’t get too technical.

But It’s very exciting what we’re seeing with NASH.

And we think that that same Mechanism of Action likely is what’s applying to some of the defect in long-haulers, but a host of other indications including stroke, where we’re seeing paresthesias and stroke fatigue get better, to perhaps implications with this particular immunomodulatory defect with diabetic patients, for example. Why some may have worse cases than others. There’s a whole lot of research.

NP
You are working with a laboratory yourself directly now that is testing leronlimab for many different biomarkers that I’m very excited for the -- everyone to know about as soon as you give us the green light to talk about it.

CR
Biomarker was one of the first initiatives. By doing the biomarkers, that helps us be able to select which patients we think would respond. Part of that is also understanding the Mechanism of Action. And knowing all of that helps us better design clinical trials. So our upcoming long-haulers trial, we spent a lot of time into that, a lot of the development actually happened through the biomarker lab.

And what we’re seeing actually in NASH as well.

And we’re just started with the biomarkers, so I look forward to a lot of trials that we can actually accelerate faster by identifying those patients that we can help them better with, that have that predisposition.

SK
Yeah, and Nader, Chris brings up a very good point here, and I think it’s something I want everybody to understand. I mean, originally I got involved in the molecule because I wanted to see -- it never made sense to me why you would wait for a virus to infect the cell and start making billions of copies rather than block it in the outset, right? Why wouldn’t you ever protect healthy cells from viral entry?

But Chris brought up something very important: immunomodulation and NASH, and whether you pick your target of PR [?] or FXR or GLP or galectin proteins. This is different. This is about CCR5 and immunomodulation. We know that CCR5 is present on hepatocytes. We know that CCR5 is present on stellate cells. Stellate cells are what produce the scar tissue in the liver. So this is really a unique approach in NASH that we think has a high likelihood of success based on immunomodulation.

But the same process applies to cancer. It’s about controlling the the tumor microenvironment and immunomodulation.

That’s what’s unique about leronlimab. We started with one thing, we just wanted to protect healthy cells from viral entry, and now we’re finding a whole new aspect of different therapeutic indications.

CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Four Pending Deals Put Shareholder Terms Under Scrutiny

Updated Category News Views 55

Four corporate transactions landed under a legal microscope on November 18, and that is never background noise for shareholders trying to judge whether the paperwork matches the price. Halper Sadeh LLC says it is investigating proposed deals involving WaFd, Personalis, Dana and Baldwin Group for possible federal securities-law violations and/or fiduciary-duty breaches....

Continue Reading
Novo and nference Push Whole-Body Data Into Research

Updated Category News Views 0

Cardiometabolic medicine has spent too long staring at single numbers while the rest of the body keeps waving its arms. Novo Nordisk’s newly announced collaboration with nference is an attempt to widen that lens, combining Novo’s clinical-trial research with nference’s AI technology and federated healthcare data network. The target is not small: obesity, diabetes,...

Continue Reading
PSEG Declares $0.67 Fourth-Quarter 2026 Cash Dividend

Updated Category News Views 159

A 67-cent utility dividend rarely sets the tape on fire, and that is precisely the point. Public Service Enterprise Group declared a regular fourth-quarter 2026 common-stock dividend of $0.67 per share, payable on or before December 31 to shareholders of record on December 10. For owners of NYSE:PEG, this is the sort of announcement that belongs in the “steady as she...

Continue Reading
Caracal’s $200K VMI Pledge Targets Cadet Affordability

Updated Category News Views 197

A tuition award can still leave a brutal hole in the budget. That is the plain fact sitting underneath Caracal Products & Services’ $200,000 commitment to Virginia Military Institute. Federal ROTC scholarships can cover tuition, but VMI says room, board and quartermaster fees average about $15,000 annually. For a student who has done everything right—earned the ROTC...

Continue Reading
Yeahka Bids to Lead AI Shopping Evolution

Updated Category News Views 115

AI Shopping: A New Frontier or A Sisyphean Task? The evolution of AI from sassy recommendation tools to transaction-executing agents is shaking up the retail sector. Enter Stage Left: Yeahka Limited (9923.HK), a payment tech outfit that's wading into this murky digital swamp. With YeahPay and Fushi Tech, they're trying to hammer out a blueprint for AI-friendly commerce...

Continue Reading
New Flight Charters Puts a Cap on Winter Surprises

Updated Category News Views 175

Ice on a wing is routine; ice on an invoice is where charter customers start muttering. New Flight Charters says it will again absorb de-icing and hangar charges this winter, up to $2,500 per trip, marking the seventh consecutive season for the program. In a business where the headline quote can look tidy and the final bill can arrive wearing muddy boots, that is a...

Continue Reading
ETCO Targets the Unflashy Weak Link in Battery Storage

Updated Category News Views 0

A battery cabinet can look impressive right up until one lousy connection becomes the problem nobody budgeted for. ETCO Incorporated’s new lineup of standard and custom connectors and terminals goes after that unglamorous part of battery energy storage systems: the physical handoff points carrying power, grounding equipment, and tying auxiliary components together. It...

Continue Reading
ZAKSIMLAB Tests Kombucha and Salmon Snack Pairing in Cafes

Updated Category News Views 148

A fish-based chip beside a fizzy tea mix is an odd little commercial wager, and that is exactly why ZAKSIMLAB's latest move deserves a look. The Seoul food brand launched Salmon Crunch Protein Chips in September, then put the snack next to its powdered kombucha at the 2026 Cafe & Bakery Fair Season 2. This is not a grand earnings story; no sales, pricing, store-count, or...

Continue Reading
Mining's Biodiversity Map Sharpens Location Risks

Updated Category News Views 11

Twelve thousand pins on a map do not settle the mining industry's nature problem, but they do make it much harder to pretend the problem is evenly spread. ICMM's new Global Mining and Metals Biodiversity Dataset overlays 12,000 large-scale formal mining, smelting, refining and processing facilities with ecosystem-condition and conservation indicators. For investors...

Continue Reading
SteriLance Aims for Smoother Pricks with NanoSense Move

Updated Category News Views 72

Revamping the Lancing Game Out there in Suzhou, SteriLance Medical is steering clear of just chasing meter accuracy—do enough folks even care about glorified electronics?—they're zeroing in on the needle part of the blood glucose test, the part that pricks your finger every damn day. Yep, this new initiative is inviting blood glucose monitoring (BGM) brands to embrace...

Continue Reading

Top 5 Most Recently Viewed Articles

Aterian Prepares for Upcoming Earnings Call This Quarter

Updated Category News Views 141

Aterian's Upcoming Financial Results Announcement Aterian, Inc. (Nasdaq: ATER), a prominent player in the consumer products sector, is gearing up to reveal its financial performance for the second quarter. Scheduled for Wednesday in the coming week, this announcement will take place after market closure, providing investors with valuable insights into the company’s...

Continue Reading
Updated Disclosure Insights for Balanced Commercial Property Trust

Updated Category News Views 70

Understanding the Recent Disclosure from Rathbones Group Plc Regarding Balanced Commercial Property Trust Limited This article offers a crucial overview of the recent disclosure made by Rathbones Group Plc about its interests in Balanced Commercial Property Trust Limited. Grasping these disclosures is essential for investors who want to effectively maneuver through the...

Continue Reading
TerraVolta Resources Secures Major Funding for Lithium Project

Updated Category News Views 219

TerraVolta Resources Lands Major Funding for Lithium Initiative Exciting developments are unfolding in the critical minerals sector as TerraVolta Resources, LLC, a key player in this field, has been chosen to negotiate a substantial $225 million funding award from the U.S. Department of Energy (DOE). This funding is set to support the establishment of a groundbreaking...

Continue Reading
Shining Moments of Natural Diamonds at the Golden Globes

Updated Category News Views 142

Shining Moments of Natural Diamonds at the Golden Globes This year's Golden Globes red carpet was captivating, showcasing natural diamonds that enchanted audiences and attendees alike. Rather than adhering to the conventional white diamond look, celebrities embraced a vibrant palette of colored diamonds. This trend was not just about sparkle but deeply reflected...

Continue Reading
iQIYI Plans Major Offering of Convertible Senior Notes

Updated Category News Views 122

iQIYI Plans a Significant Offering of Convertible Senior Notes iQIYI, Inc. (Nasdaq: IQ) is making headlines with its recent announcement regarding a substantial offering. The company plans to issue $300 million in convertible senior notes, reflecting its ongoing commitment to strengthen its financial position and enhance shareholder value. Details of the Convertible...

Continue Reading